Found 69 clinical trials
A Multicenter, Open-Label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First Line Treatment of Subjects with Advanced Renal Cell Carcinoma
A Multicenter, Open-Label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First Line Treatment of
- 222 views
- 25 Mar, 2021
- 1 location
ABSORB III - A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesions Absorb™ is an investigational bioabsorbable vascular scaffold manufactured by Abbott. Absorb™ is referred to as a scaffold to indicate that it is a temporary structure.
ABSORB III - A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesions Absorb™ is an
- 120 views
- 25 Mar, 2021
- 1 location
A Phase I/Ib, Open-label, Multi-center Study of DFF332 as a Single Agent and in Combination With Everolimus or IO Agents in Patients With Advanced/Relapsed ccRCC and Other Malignancies With HIF2α Stabilizing Mutations
tested at different doses as single agent and in combination with Everolimus (RAD001, an mTOR inhibitor), and also in combination with Spartalizumab (PDR001, an anti-PD1) plus Taminadenant (NIR178, an
- 16 views
- 24 Oct, 2022
- 10 locations
Itacitinib + Everolimus in Hodgkin Lymphoma
This is an open-label, single-group, Phase I/II study of itacitinib in combination with everolimus in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL).
- 1 views
- 04 Oct, 2022
- 1 location
AERO: Adjuvant EveRolimus Outcomes in Laryngotracheal Stenosis
result in communication disability and high mortality rates due to the obstructed airway. The proposed Adjuvant EveRolimus Outcomes (AERO) trial is proof-of-concept study using the immunosuppressant drug
- 0 views
- 25 Oct, 2022
- 1 location
Everolimus in Treating Patients With Recurrent or Progressive Low-Grade Glioma
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is
- 24 views
- 07 Nov, 2020
- 1 location
CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer
To evaluate the feasibility of administering HCQ, EVE or the combination in patients who have completed primary therapy for breast cancer and harbor bone marrow disseminated tumor cells.
- 24 views
- 14 Jun, 2022
- 1 location
Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients
greater effect in everolimus vs. tacrolimus treated LTR, thus providing the rationale for a subsequent clinical trial to utilize EPO in combination with everolimus as a more successful pathway toward
- 0 views
- 02 May, 2022
- 1 location
Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
combination with nivolumab plus ipilimumab as first line therapy and in combination with lenvatinib plus everolimus as 2nd line therapy post 1st line failure.
- 0 views
- 04 Oct, 2022
- 8 locations
SELUTION SLR™ 014 In-stent Restenosis
treatment with either the SELUTION SLR™ DEB or SOC to include contemporary DES (zotarolimus-eluting stents and everolimus-eluting stents only) or non-DEB BA. A maximum of 418 randomized subjects will be
- 0 views
- 23 Apr, 2022
- 2 locations